The CRISPR-Cas9 technology quickly became a widely used tool for biomedical research. Developing therapies based on it takes longer; but by now some CRISPR-Cas9-based therapies have reached the phase of clinical evaluation. What can we expect from CRISPR-Cas9 and follow-on technologies in the lab and in therapy in the near future? Which handicaps have turned out to slow down the development of CRISPR-based therapies? Can and should CRISPR-Cas9 be used for germline therapy?

Moderator: Dr. André Cohnen, VP, Head of Genomic Medicine at Bayer Pharmaceuticals